The present invention provides a method of preparing a lipid nanoparticle dispersion using a twin screw extruder. The inventive lipid nanoparticle dispersion includes greater than 25% lipophilic content in the form of lipidic nanoparticles with volume average particle size less than 120 nm dispersed in a continuous aqueous matrix with greater than 0.1 percent of tetrahydrocannabinol.

An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core-shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.

This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.

Combinations of nanoparticle-encapsulated cargo entities and methods of making and using same.

The present disclosure relates to improved supraparticles loaded with high levels of payload and methods for their production. Such supraparticles may be used in a range of therapeutic applications, for example, to improve growth or survival of cells and/or treat disease.

Disclosed are pharmaceutical compositions including a plurality of nanoparticles including a compound of the following structure (1) or a pharmaceutically acceptable salt thereof. Also disclosed are methods of their use and preparation.

##STR00001##

In a first aspect, the invention provides a polymeric nanoparticle comprising at least one polycationic polymer; at least one polyanionic polymer; and a therapeutically effective amount of at least one therapeutic agent.

In a second aspect, the invention provides a method for the preparation of a polymeric nanoparticle according to the first aspect; the method comprising the steps of: (i)admixing the at least one polyanionic polymer with the at least one therapeutic agent; and (ii) introducing to the mixture of (i), to the at least one polycationic polymer.

In a third aspect, the invention provides a polymeric nanoparticle according to the first aspect of the present invention, or a polymeric nanoparticle prepared according to the second aspect of the present invention; for use in the treatment of an inflammatory and/or arthritic disorder caused by or associated with dysfunctional nuclear receptor signalling.

Herein is provided a recombinant tumor-selective viral particle comprising a nucleic acid encoding a recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, said recombinant polypeptide comprising: at least one targeting moiety for directing said EV to said at least one target molecule expressed by said at least one target cell; at least one EV-anchoring polypeptide; and at least one intravesicular polypeptide. The viral particle may be from an oncolytic viruses. Recombinant polypeptides for programming EVs to target particular molecules are also provided. Also described are therapeutic EVs for delivering payload polypeptides (and/or cargo molecules) to target cells, e.g., in vaccine or cell-free “CAR-T”-like applications, along with EVs for recruiting immune cells to target cells in EV-mediated BiTE -like applications. Oncolytic viruses may also be engineered to infect tumor cells and shed programmed EVs, yielding additional therapeutic effects.

The present disclosure provides nanoparticle compositions comprising i) a polymeric nanoparticle, ii) one or more ligands conjugated to the polymeric nanoparticle, and iii) naloxone. The disclosure also provides methods and pharmaceutical compositions comprising the nanoparticle compositions for use in treating patients with various disease states.

Methods, systems, and devices are disclosed for encapsulating biological entities with preservation of their biological activity. In one aspect, a method of encapsulating a biological entity includes templating a biocompatible material onto a biological structure to form a coating structure enclosing the biological structure, the coating structure having a size in the nanometer range, in which the coated biological structure preserves its biological activity within the coating structure. In some implementations of the method, the biological structure includes a virus and the biocompatible material includes silica.